François Alhenc‐Gelas

9.2k total citations · 1 hit paper
122 papers, 6.9k citations indexed

About

François Alhenc‐Gelas is a scholar working on Genetics, Cardiology and Cardiovascular Medicine and Molecular Biology. According to data from OpenAlex, François Alhenc‐Gelas has authored 122 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Genetics, 61 papers in Cardiology and Cardiovascular Medicine and 33 papers in Molecular Biology. Recurrent topics in François Alhenc‐Gelas's work include Coagulation, Bradykinin, Polyphosphates, and Angioedema (66 papers), Renin-Angiotensin System Studies (54 papers) and Hormonal Regulation and Hypertension (28 papers). François Alhenc‐Gelas is often cited by papers focused on Coagulation, Bradykinin, Polyphosphates, and Angioedema (66 papers), Renin-Angiotensin System Studies (54 papers) and Hormonal Regulation and Hypertension (28 papers). François Alhenc‐Gelas collaborates with scholars based in France, United States and Germany. François Alhenc‐Gelas's co-authors include Florent Soubrier, J Allegrini, Pierre Corvol, François Cambien, O. Costerousse, Joël Ménard, M. Lopez, Laurence Tiret, Philippe Amouyel and Alun Evans and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

François Alhenc‐Gelas

121 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction

1992 1.6k citations François Alhenc‐Gelas, Florent Soubrier et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
François Alhenc‐Gelas France	41	3.9k	2.4k	2.0k	1.6k	1.1k	122	6.9k
Klaus Lindpaintner United States	46	4.1k 1.1×	2.3k 0.9×	2.0k 1.0×	467 0.3×	692 0.6×	138	8.2k
F Alhenc‐Gelas France	16	3.1k 0.8×	1.9k 0.8×	1.2k 0.6×	518 0.3×	669 0.6×	25	4.9k
Brigitte Rigat Canada	21	3.9k 1.0×	2.6k 1.1×	1.2k 0.6×	390 0.2×	901 0.8×	32	6.5k
Toshihiro Ichiki Japan	46	3.5k 0.9×	2.1k 0.9×	3.4k 1.7×	371 0.2×	671 0.6×	111	7.4k
C. Hübert France	12	2.8k 0.7×	1.7k 0.7×	1.0k 0.5×	375 0.2×	559 0.5×	24	4.4k
V J Dzau United States	35	3.8k 1.0×	1.8k 0.7×	2.2k 1.1×	230 0.1×	458 0.4×	76	5.9k
Fuad N. Ziyadeh United States	66	2.1k 0.5×	2.9k 1.2×	6.3k 3.2×	494 0.3×	847 0.8×	161	15.7k
Naoharu Iwai Japan	48	2.7k 0.7×	1.9k 0.8×	3.7k 1.9×	193 0.1×	531 0.5×	126	7.1k
Harry S. Margolius United States	38	1.1k 0.3×	965 0.4×	1.3k 0.6×	2.3k 1.4×	556 0.5×	102	4.2k
Hiroshi Iwao Japan	48	3.2k 0.8×	1.2k 0.5×	3.7k 1.9×	305 0.2×	511 0.5×	249	8.2k

Countries citing papers authored by François Alhenc‐Gelas

Since Specialization

Citations

This map shows the geographic impact of François Alhenc‐Gelas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by François Alhenc‐Gelas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites François Alhenc‐Gelas more than expected).

Fields of papers citing papers by François Alhenc‐Gelas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by François Alhenc‐Gelas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by François Alhenc‐Gelas. The network helps show where François Alhenc‐Gelas may publish in the future.

Co-authorship network of co-authors of François Alhenc‐Gelas

This figure shows the co-authorship network connecting the top 25 collaborators of François Alhenc‐Gelas. A scholar is included among the top collaborators of François Alhenc‐Gelas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with François Alhenc‐Gelas. François Alhenc‐Gelas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mohammedi, Kamel, Michel Marre, & François Alhenc‐Gelas. (2024). Genetic predisposition to nephropathy and associated cardiovascular disease in people with type 1 diabetes: role of the angiotensinI-converting enzyme (ACE), and beyond; a narrative review. Cardiovascular Diabetology. 23(1). 453–453. 3 indexed citations

Mohammedi, Kamel, Louis Potier, Séverine Dubois, et al.. (2021). Association Between the ACE Insertion/Deletion Polymorphism and Risk of Lower-Limb Amputation in Patients With Long-Standing Type 1 Diabetes. Diabetes Care. 45(2). 407–415. 3 indexed citations

Mohammedi, Kamel, Séverine Dubois, Pierre Gourdy, et al.. (2021). ACE I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or All-Cause Death in Patients With Type 1 Diabetes. Diabetes Care. 44(6). 1377–1384. 6 indexed citations

Alhenc‐Gelas, François, Nadine Bouby, & Jean‐Pierre Girolami. (2019). Kallikrein/K1, Kinins, and ACE/Kininase II in Homeostasis and in Disease Insight From Human and Experimental Genetic Studies, Therapeutic Implication. Frontiers in Medicine. 6. 136–136. 18 indexed citations

Adam, Clovis, et al.. (2015). Abstract P159: Effect of Pharmacological Kinin Receptor Activation on Brain Damage and Mortality in Experimental Cerebral Ischemia in Non-diabetic and Diabetic Mice. Hypertension. 66(suppl_1). 1 indexed citations

Potier, Louis, Ludovic Waeckel, Frédéric Fumeron, et al.. (2014). Tissue kallikrein deficiency, insulin resistance, and diabetes in mouse and man. Journal of Endocrinology. 221(2). 297–308. 7 indexed citations

Potier, Louis, Ludovic Waeckel, Catherine Chollet, et al.. (2013). Selective Kinin Receptor Agonists as Cardioprotective Agents in Myocardial Ischemia and Diabetes. Journal of Pharmacology and Experimental Therapeutics. 346(1). 23–30. 49 indexed citations

Potier, Louis, et al.. (2013). Pathophysiology of genetic deficiency in tissue kallikrein activity in mouse and man. Thrombosis and Haemostasis. 110(9). 476–483. 22 indexed citations

Velho, Gilberto, Nadine Bouby, Samy Hadjadj, et al.. (2013). Plasma Copeptin and Renal Outcomes in Patients With Type 2 Diabetes and Albuminuria. Diabetes Care. 36(11). 3639–3645. 75 indexed citations

10.

Stone, Oliver A., Christine Richer, Costanza Emanueli, et al.. (2009). Critical Role of Tissue Kallikrein in Vessel Formation and Maturation. Arteriosclerosis Thrombosis and Vascular Biology. 29(5). 657–664. 48 indexed citations

11.

Pons, Sandrine, Violaine Griol‐Charhbili, Christophe Heymes, et al.. (2008). Tissue kallikrein Deficiency Aggravates Cardiac Remodelling and Decreases Survival after Myocardial Infarction in Mice. European Journal of Heart Failure. 10(4). 343–351. 22 indexed citations

12.

Roisman, G., Claire Danel, J Lacronique, François Alhenc‐Gelas, & Daniel Dusser. (1999). Decreased expression of angiotensin-converting enzyme in the airway epithelium of asthmatic subjects is associated with eosinophil inflammation☆☆☆★. Journal of Allergy and Clinical Immunology. 104(2). 402–410. 10 indexed citations

13.

Metzger, Roman, Rainer M. Bohle, Katharina Pauls, et al.. (1999). Angiotensin-converting enzyme in non-neoplastic kidney diseases. Kidney International. 56(4). 1442–1454. 81 indexed citations

14.

Williams, Tracy Ann, et al.. (1996). A study of chimeras constructed with the two domains of angiotensin I-converting enzyme. Biochemical Pharmacology. 51(1). 11–14. 19 indexed citations

15.

Corvol, Pierre, François Alhenc‐Gelas, & F Soubrier. (1993). L'endothélium, site de production et de métabolisme des peptides vaso-actifs. médecine/sciences. 9(10). 1050–1050. 7 indexed citations

16.

Soubrier, Florent, Lei Wei, Christine Hübert, et al.. (1993). Molecular biology of the angiotensin I converting enzyme: II. Structure-function. Gene polymorphism and clinical implications. Journal of Hypertension. 11(6). 599–604. 56 indexed citations

17.

Costerousse, Olivier, Emmanuel Jaspard, & François Alhenc‐Gelas. (1993). Molecular and genetic aspects of dipeptidyl carboxypeptidase I (the angiotensin 1 converting enzyme). Expression in the immune system. 3(3). 217–226. 6 indexed citations

18.

Mounier, Françoise, N Hinglais, Mireille Sich, et al.. (1987). Ontogenesis of angiotensin-I converting enzyme in human Kidney. Kidney International. 32(5). 684–690. 34 indexed citations

19.

Imbert–Teboul, Martine, et al.. (1984). Kallikrein along the rabbit microdissected nephron: A micromethod for its measurement. Pflügers Archiv - European Journal of Physiology. 401(1). 27–33. 43 indexed citations

20.

Zimmerman, Earl A., et al.. (1983). Angiotensin-Converting Enzyme in Epithelial and Neuroepithelial Cells. Neuroendocrinology. 37(1). 32–40. 130 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact